Skeletal muscle-specific eukaryotic translation initiation factor 2α phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism.
Saved in:
| Title: | Skeletal muscle-specific eukaryotic translation initiation factor 2α phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism. |
|---|---|
| Authors: | Miyake M; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Nomura A; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Ogura A; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Takehana K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Kitahara Y; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Takahara K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Tsugawa K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Miyamoto C; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Miura N; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Sato R; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Kurahashi K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Harding HP; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Oyadomari M; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Ron D; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Oyadomari S; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom oyadomar@tokushima-u.ac.jp. |
| Source: | FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2016 Feb; Vol. 30 (2), pp. 798-812. Date of Electronic Publication: 2015 Oct 20. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 26487695 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Skeletal muscle-specific eukaryotic translation initiation factor 2α phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Miyake+M%22">Miyake M</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Nomura+A%22">Nomura A</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ogura+A%22">Ogura A</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Takehana+K%22">Takehana K</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kitahara+Y%22">Kitahara Y</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Takahara+K%22">Takahara K</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Tsugawa+K%22">Tsugawa K</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Miyamoto+C%22">Miyamoto C</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Miura+N%22">Miura N</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Sato+R%22">Sato R</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kurahashi+K%22">Kurahashi K</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Harding+HP%22">Harding HP</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Oyadomari+M%22">Oyadomari M</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ron+D%22">Ron D</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Oyadomari+S%22">Oyadomari S</searchLink>; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom oyadomar@tokushima-u.ac.jp. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228804484%22">FASEB journal : official publication of the Federation of American Societies for Experimental Biology</searchLink> [FASEB J] 2016 Feb; Vol. 30 (2), pp. 798-812. <i>Date of Electronic Publication: </i>2015 Oct 20. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Federation+of+American+Societies+for+Experimental+Biology%22">Federation of American Societies for Experimental Biology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8804484 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1530-6860 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2208926638%22">08926638 </searchLink><i>NLM ISO Abbreviation: </i>FASEB J <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=26487695 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1096/fj.15-275990 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 798 Titles: – TitleFull: Skeletal muscle-specific eukaryotic translation initiation factor 2α phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Miyake M – PersonEntity: Name: NameFull: Nomura A – PersonEntity: Name: NameFull: Ogura A – PersonEntity: Name: NameFull: Takehana K – PersonEntity: Name: NameFull: Kitahara Y – PersonEntity: Name: NameFull: Takahara K – PersonEntity: Name: NameFull: Tsugawa K – PersonEntity: Name: NameFull: Miyamoto C – PersonEntity: Name: NameFull: Miura N – PersonEntity: Name: NameFull: Sato R – PersonEntity: Name: NameFull: Kurahashi K – PersonEntity: Name: NameFull: Harding HP – PersonEntity: Name: NameFull: Oyadomari M – PersonEntity: Name: NameFull: Ron D – PersonEntity: Name: NameFull: Oyadomari S IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2016 Feb Type: published Y: 2016 Identifiers: – Type: issn-electronic Value: 1530-6860 Numbering: – Type: volume Value: 30 – Type: issue Value: 2 Titles: – TitleFull: FASEB journal : official publication of the Federation of American Societies for Experimental Biology Type: main |
| ResultId | 1 |
